NCT00273871已完成3 期
A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 190 人开始时间: 2002年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 190
- 主要终点
- Difference between treatment groups in renal function at 12 months.
研究概览
简要总结
The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age over 18
- •Treatment with a calcineurin inhibitor
- •Patients with mild to moderate renal insufficiency
排除标准
- •Patients with acute rejection
- •Patients who received a transplant more than 10 years ago
结局指标
主要结局
Difference between treatment groups in renal function at 12 months.
次要结局
- Incidence of acute rejection, patient and graft survival at 12 months, labs and physical examinations, quality of life etc.
研究者
相似试验
已完成
3 期
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant RecipientsRenal TransplantationNCT00038948Wyeth is now a wholly owned subsidiary of Pfizer830
撤回
1 期
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg CellsAutoimmune DiseasesNCT00777400University of California, San Francisco
已完成
4 期
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant RecipientsGraft RejectionKidney FailureNCT00369382Wyeth is now a wholly owned subsidiary of Pfizer121
已完成
4 期
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft RecipientsRenal Transplant RejectionNCT00866879Northwestern University275
已完成
4 期
The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver TransplantLiver Transplant RecipientsNCT00275639Mayo Clinic62